




RealRate

PHARMACEUTICAL 2018

Regen Biopharma Inc
Rank 328 of 332



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Regen Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regen Biopharma Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 11% points. The greatest weakness of Regen Biopharma Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 170% points.

The company's Economic Capital Ratio, given in the ranking table, is 22%, being 230% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	478
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,863
Liabilities, Non-Current	0
Other Assets	466
Other Compr. Net Income	168
Other Expenses	649
Other Liabilities	332
Other Net Income	-3,328
Other Revenues	110
Property and Equipment	0
Research and Development	1,150
Selling, General and Administrative Expense	822

Output Variable	Value in 1000 USD
Assets	944
Liabilities	6,196
Expenses	2,621
Revenues	110
Stockholders Equity	-5,251
Net Income	-5,839
Comprehensive Net Income	-5,755
BaseVar	6,683
ECR before Limited Liability	-482%
Economic Capital Ratio	22%